클로메스트로네

클로메스트로네
임상 데이터
상호	아테롤로, 아테란, 콜레스트렐, 이포스클레론, 리프로텐, 페르스클레롤
기타 이름	SC-8246; 16α-클로로에스트론 3-메틸에테르; 16α-클로로-3-메톡시에스트라-1, 3, 5(10)-트리엔-17-온
루트; 행정부.	입으로
약물 클래스	에스트로겐, 에스트로겐 에테르
식별자
	IUPAC 이름 (8R,9S,13S,14S,16R)-16-클로로-3-메톡시-13-메틸-7,8,9,11,12,14,15,16-옥타히드로-6H-시클로펜타[a]페난트렌-17-온;
CAS 번호	4091-75-2;
PubChem CID	107501;
켐스파이더	96732;
유니	P1L5F7667L;
CompTox 대시보드 (EPA )	DTXSID50878418 ;
ECHA 정보 카드	100.021.669
화학 및 물리 데이터
공식	C19H23클론O2
몰 질량	318.84 g/g−1/g/g/sqm
3D 모델(JSmol)	인터랙티브 이미지;
	미소 CC12CC3C(C1CC(C2=O)Cl)CCC4=C3C=CC(=C4)조직;
	인치 InChI=1S/C19H23ClO2/c1-8-8-7-14-13-6-4-12(22-2)9-11(13)3-5-15(14)16(19)10-17(20)18(19)21/h4,6,9,14-17,8,8,8,8,8,7; 키: UQIPVSBPFZSWGD-ILYVXUQDSA-N;

클로메스트론(상표명 Arterolo, Atheran, Colestrel, Iposclerone, Liproten, Persclerol, 기타), 또는 16α-클로로에스트론 3-메틸에테르라고도 알려진 SC-8246은 에스트론에서 유래한 합성 스테로이드성 약 에스트로겐으로, 항에스테르 처리제로 사용됩니다.임상연구에서 대부분의 환자에게서 유방 압통,^[3]^[4] 성욕 상실, 피로 또는 탈락을 포함한 일부 에스트로겐성 부작용이 관찰되었지만, 그것은 최소한의 여성화를 생성하면서 혈청 지질 프로파일에 이로운 영향을 미친다고 한다.이 약은 미타트리엔디올과 유사하며 두 에스트로겐은 유사한 약물 프로파일을 ^[5]가지고 있다.클로메스트론은 1958년 문헌에 기술되었고 그 ^[1]직후 의료용으로 도입되었다.

「」를 참조해 주세요.

레퍼런스

^ ^a ^b J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 297–298. ISBN 978-1-4757-2085-3.
^ Gregory Pincus (22 October 2013). Hormones and Atherosclerosis: Proceedings of the Conference Held in Brighton, Utah, March 11-14, 1958. Elsevier Science. pp. 253–374. ISBN 978-1-4832-7064-7.
^ RIVIN AU (1959). "SC 8246, a new estrogen analog: lipoprotein effects with minimal feminization". Metab. Clin. Exp. 8: 704–8. PMID 14437693. SC-8246 (16-alpha chlorestrone 3-methyl ether) was administered for periods of six to twelve months to 20 male survivors of acute myocardial infarction ranging in age from 30 to 63 years. A significant decrease in serum cholesterol concentration occurred in only 6 of 13 patients with an initial cholesterol level above 250 mg. per 100 ml., and there was no change in the other 7. Of 7 initial cholesterol levels below 250 mg. per 100 ml., no level decreased, 3 increased, and 4 were unchanged. In 9 of 11 patients with an initial alpha:beta lipoprotein ratio of less than 20 per cent, a significant increase occurred, but no change in the other 2. Among 9 subjects with a ratio initially above 20 per cent, a further increase occurred in 8 while taking the drug. This estrogen appeared to have an advantage in terms of lessening side-effects. Mild breast tenderness or gynecomastia occurred in 15 of the 17 patients with a "favorable" lipoprotein change. When the dosage was reduced to 5 mg. daily or every other day, the lipoprotein effect in 8 of them could be sustained while the breast changes disappeared. Libido disappeared from 2 patients and was diminished in 1 other. Other side-effects were nausea in 1 patient, loss of ambition in 5, and itching or dryness of the skin in 4.
^ WINSOR T, FISHER EK, PAYNE JH (1959). "A method for the study of peripheral arteriosclerosis". J Am Geriatr Soc. 7 (2): 167–74. doi:10.1111/j.1532-5415.1959.tb01062.x. PMID 13630690. S2CID 46048052.
^ Cancer Chemotherapy Abstracts. Information Resources Press. January 1960. p. 143.

스테로이드제에 대한 이 기사는 엉터리이다.위키피디아를 확장함으로써 위키피디아를 도울 수 있습니다.

비뇨기 계통에 관한 이 약물 기사는 엉터리이다.위키피디아를 확장함으로써 위키피디아를 도울 수 있습니다.

심혈관계와 관련된 이 약물 기사는 엉터리이다.위키피디아를 확장함으로써 위키피디아를 도울 수 있습니다.

[Elks2014-1] J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 297–298. ISBN 978-1-4757-2085-3.

[Pincus2013-2] Gregory Pincus (22 October 2013). Hormones and Atherosclerosis: Proceedings of the Conference Held in Brighton, Utah, March 11-14, 1958. Elsevier Science. pp. 253–374. ISBN 978-1-4832-7064-7.

[pmid14437693-3] RIVIN AU (1959). "SC 8246, a new estrogen analog: lipoprotein effects with minimal feminization". Metab. Clin. Exp. 8: 704–8. PMID 14437693. SC-8246 (16-alpha chlorestrone 3-methyl ether) was administered for periods of six to twelve months to 20 male survivors of acute myocardial infarction ranging in age from 30 to 63 years. A significant decrease in serum cholesterol concentration occurred in only 6 of 13 patients with an initial cholesterol level above 250 mg. per 100 ml., and there was no change in the other 7. Of 7 initial cholesterol levels below 250 mg. per 100 ml., no level decreased, 3 increased, and 4 were unchanged. In 9 of 11 patients with an initial alpha:beta lipoprotein ratio of less than 20 per cent, a significant increase occurred, but no change in the other 2. Among 9 subjects with a ratio initially above 20 per cent, a further increase occurred in 8 while taking the drug. This estrogen appeared to have an advantage in terms of lessening side-effects. Mild breast tenderness or gynecomastia occurred in 15 of the 17 patients with a "favorable" lipoprotein change. When the dosage was reduced to 5 mg. daily or every other day, the lipoprotein effect in 8 of them could be sustained while the breast changes disappeared. Libido disappeared from 2 patients and was diminished in 1 other. Other side-effects were nausea in 1 patient, loss of ambition in 5, and itching or dryness of the skin in 4.

[pmid13630690-4] WINSOR T, FISHER EK, PAYNE JH (1959). "A method for the study of peripheral arteriosclerosis". J Am Geriatr Soc. 7 (2): 167–74. doi:10.1111/j.1532-5415.1959.tb01062.x. PMID 13630690. S2CID 46048052.

[5] Cancer Chemotherapy Abstracts. Information Resources Press. January 1960. p. 143.

[3]

[4]

[5]

[1]

Search

클로메스트로네

네임스페이스

더

「」를 참조해 주세요.

레퍼런스

Search

클로메스트로네

「 」를 참조해 주세요.

레퍼런스

「」를 참조해 주세요.